logo-loader

Amryt Pharma's Lojuxta approved for funding as NHS treatment

Published: 20:07 10 Jul 2018 AEST

David Allmond, chief commercial officer at Amryt Pharma PLC (LON:AMYT) tells Proactive Investors their Lojuxta Homozygous Familial Hypercholesterolaemia (HoFH) treatment is to be made available to NHS patients in England.

HoFH is a rare life-threatening disorder that causes abnormally high levels of low density lipoprotein (LDL) cholesterol.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

12 hours, 50 minutes ago